INTRODUCTION

1
Human astroviruses (HAstVs) are a significant cause of acute gastroenteritis in young 2 children. While second only to rotavirus in the incidence of virally-induced gastroenteritis in 3 children (7), HAstVs are recognized as the leading cause of viral diarrhea in infants (27) . Eight 4 distinct HAstVs have been identified to date with serotype 1 being the most prevalent worldwide 5 (18). In addition to humans, members of this virus family infect a variety of other young 6 mammals and birds causing disease ranging from diarrhea to nephritis (18). Astroviruses are 7 small, non-enveloped, icosahedral particles with a single-stranded, messenger-sense RNA 8 genome (~7 kb) that is organized into 3 ORFs: ORFs 1a and 1b encode non-structural proteins 9
(11, 16, 34) whereas ORF2 encodes the coat protein (CP) precursor (16, 32) . CP precursors 10 assemble into particles, encapsidating the viral genome and are subsequently cleaved 11 extracellularly by trypsin, which renders the virion infectious (1, 20) . 12 The pathogenesis and immunity to HAstVs is poorly understood. Virions have been 13 identified in intestinal epithelial cells of children with diarrhea, correlating with fecal shedding of 14 the virus (reviewed in 21). However, HAstV-induced diarrhea appears not to result in significant 15 cell death or inflammation in humans (26) and astrovirus animal models have suggested that the 16 innate immune system may contribute to pathogenesis (reviewed in 13). In an attempt to
The inoculum was removed and medium containing 2 µg/ml of trypsin was added; cells were To measure the amount of C3-fragments deposited on zymosan, 20 µl NHS was incubated 1 alone, with 9 µg CP or 1 µg CVF and all samples were brought up to 70 µl with GVBS ++ buffer 2 for 1 h at 37 o C. After incubation, the volume was adjusted to 1 ml with GVBS ++ buffer and 450 3 µl was aliquoted, 3 µg C1 was added to the indicated samples and then 25 µl of activated 4 zymosan (Sigma-Aldrich) was added to all samples. After a 10 min incubation at 37 o C, the 5 samples were washed twice with GVBS − − buffer, incubated with 25 mM methylamine for 1 h at 6 37 o C, to release bound C3-fragments and the supernatant collected. A C3 ELISA was performed 7 on the samples using a polyclonal antibody to C3 and analyzed as described above. 8
Real-time reverse transcription PCR. To quantify HAstV stocks, a real-time PCR method 9 was developed. To isolate total RNA, 40 µl of CaCo-2 cell lysates infected with HAstV 1, 2, 3 10 and 4 were diluted 1:5 in 1 × minimum essential medium. RNA was then extracted using Trizol 11 (Invitrogen) per manufacturer's instructions. Following isolation, RNA was treated with DNase 12 I (Promega) for 30 min at 37ºC and the enzyme was then inactivated at 65ºC for 10 min. RNA 13 was stored at -80ºC. 14 One-step real-time RT-PCR was performed using the iCycler IQ TM system (Bio-Rad). The 15 real-time RT-PCR reaction was assembled using the iScrip TM One-Step RT -PCR Kit with Syber 16 final concentration; primer sequences provided upon request), 0.5 µl iScript Reverse 20
Transcriptase for One-Step RT PCR, 6.0 µl sterile water and 5.0 µl of the total RNA (isolated as 21 described above). cDNA synthesis was achieved by incubating the reaction for 10 min at 50ºC, 22 followed by inactivation of iScript RT at 95ºC for 5 min. PCR cycling and detection included 45 23
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on August 30, 2017 by guest http://jvi.asm.org/ Downloaded from cycles of incubation at 95ºC for 10 sec, 55ºC for 30 sec, and 72ºC for 30 sec, respectively. For 1 the melt curve, samples were incubated at 95ºC for 1 min, 57ºC for 1 min, followed by 80 cycles 2 of incubation for 10 sec, starting at 57ºC, and increasing at 0.5ºC increments with each 3 successive cycle. To generate a standard curve, an RNA standard was prepared by T7-mediated 4 in vitro transcription (Ambion) of a genome-length cDNA clone (pAVIC) for HAstV-1 (10). 5
The RNA standard was serially diluted from 10 10 to 10 0 and the standard curve was established 6 by plotting the threshold cycle vs. log starting copy number for each dilution. Log starting copy 7 number of the viral RNA contained in the CaCo-2 cell lysate was then extrapolated from the of CVF ( Fig. 2A, shaded bars) . At 85 µl of virus-containing lysate (2.92 × 10 8 genome copies), 7 inhibition of hemolysis surpassed that of CVF (P = 0.0143). To demonstrate that the inhibition of 8 hemolytic complement activity was due to HAstV-1 virions, NHS was incubated with equivalent 9 amounts of cell lysate from uninfected cells to show that this activity was virus specific ( Fig. 2A,  10 white bars). In addition, 7.64 × 10 10 particles of sucrose-gradient-purified Flock House virus 11 (FHV), a heterologous icosahedral RNA virus that infects insects (15), was found not to inhibit 12 hemolysis (RBC lysis = 107% ± 6.57 SE, n = 3). 13
To characterize the kinetics of activity of the virions on NHS in the hemolytic complement 14 assay, a time course comparing HAstV-1 virions and CVF was conducted. Infected cell lysates 15 containing HAstV-1 particles (2.92 × 10 8 genome copies) and 1 µg CVF were incubated from 0 16 to 60 minutes in the presence of 2% NHS. At increasing time intervals, aliquots were removed 17 and exposed to sensitized RBCs. Both CVF and the virus showed similar kinetics in the 18 inhibition of hemolysis (Fig. 2B) . While CVF displayed a more pronounced suppression of 19 hemolytic activity at earlier timepoints, at the 60 minute time point virus demonstrated a stronger 20 inhibitory effect of 93% compared with only 75% suppression for CVF (P = 0.0001). 21
Other HAstV serotypes suppress hemolytic complement activity. To determine whether 22
HAstV serotypes other than the type 1 exhibit the same effects on complement activity, 23 cannot not rule out the possibility that a newly induced/overproduced cellular protein or viral 7 non-structural protein is responsible for the observed complement suppression activity. To 8 address this contingency, we isolated soluble HAstV-1 CP produced from a recombinant 9 baculovirus. While small numbers of intact virus-like particles were visualized in infected Sf21 10 cells by thin-section electron microscopy, most of the CP was in the form of aggregates (data not 11 shown). To produce soluble CP, we utilized a 4-step purification procedure in which CP 12 aggregates were initially isolated in crude form by extraction of cells with 2% NP-40 followed 13 by 0.5 mg of DNase I per ml (22). After high-speed pelleting, the CP-containing pellet was 14 resuspended in dissociation buffer with freezing overnight to solubilize the aggregated CP (25) 15 and purified further by sucrose gradient ultracentrifugation in the same buffer. During 16 centrifugation, the majority of the CP was found to peak between fractions 6-8 along with some 17 CP degradation products as analyzed by SDS-PAGE followed by Coomassie blue staining (Fig.  18 3A) and immunoblot using antibody to HAstV-1 particles (2) (Fig. 3B) . 19 SDS-PAGE analysis of the CP-containing fractions at each step of the purification procedure 20 was monitored by Coomassie blue staining ( due to a CP-specific degradation product that migrated slightly below the full-length 87 kDa 1 band. When gradient-purified CP was boiled in the presence of β-mercaptoethanol and run on a 2 7.5% SDS-PAGE gel, CP was detected at 87 kDa as expected (Fig. 4C ). However, CP that was 3 not boiled gave rise to a band that migrated just above the 250 kDa molecular weight standard 4 (Fig. 4C ). The size of this band is consistent with a trimer of CP molecules which would be 5 predicted to run at approximately 261 kDa (87 kDa × 3) and possibly represents an assembly 6 intermediate. However, fully assembled virus-like particles were not detected under these 7 dissociating conditions when analyzed by negative stain electron microscopy (data not shown). 8
Consistent with our findings, HAstV serotype 8 CP has recently been reported to form trimers in 9
in vitro translation experiments (19). We also subjected the purified CP to digestion with trypsin 10 which is normally required to cleave the viral capsid into proteins of 34, 29 and 26 kDa when 11 resolved by SDS-PAGE (1, 20) . Trypsin cleavage of the CP resulted in digestion products of 12 less than 25 kDa further demonstrating that the soluble CP was structurally different than intact 13 virus-like particles (data not shown). 14 To ascertain whether soluble CP displays complement suppressing activity as demonstrated 15 for authentic virus, we again utilized the hemolytic complement assay (Fig. 4D) factors specific for each pathway were utilized in the hemolytic complement assay. To evaluate 6 suppression of classical pathway activation by CP, NHS and factor-B-depleted (fBD) sera were 7 compared. Factor B is essential for alternative pathway activation and utilizing fBD sera allows 8 the specific testing of classical pathway activation. Both NHS and fBD serum demonstrated a 9 dose-dependent suppression of hemolysis by CP (Fig. 5A ). However, CP was considerably more 10 effective at suppressing fBD serum compared to NHS. For 3.6 µg CP, hemolysis was suppressed 11 16% for fBD serum compared with 55% for NHS (P = 0.0159). Increased inhibition when the 12 classical pathway was isolated (fBD serum) compared with when activation could occur by any 13 or all pathways (NHS) suggested that CP may more strongly suppress activation of the classical 14 pathway than the alternative pathway. As with CP, infected cell lysates containing HAstV-1 15 particles (2.92 × 10 8 genome copies) also inhibited hemolysis in fBD sera (Fig. 5B ). It should be 16 noted that fBD serum retains the same capacity for hemolysis as NHS because C3 and C5-C9 are 17 intact. It is possible that the lectin pathway may also activate under these conditions, but it is 18 currently unknown as to whether astrovirus capsids are glycosylated. 19
We tested the effect of CP and virus on the alternative pathway as well. As demonstrated in 20 only a modest effect on the suppression of hemolysis (NHS + CP). To confirm that activation 1 was limited to the alternative pathway, C2-depleted serum (C2D) was utilized in place of NHS. 2
By depleting NHS of C2 in this assay, the classical and lectin pathways are blocked and any 3 RBC lysis is due exclusively to alternative pathway activity. As with NHS, C2D serum in the 4 presence of CP only suppressed hemolysis by approximately 25% compared to C2D serum alone 5 (Fig. 6A, C2D and C2D + CP). The same results were obtained when HAstV-1 infected cell 6 lysates (2.92 × 10
8 genome copies) were tested for alternative pathway activity (Fig. 6B) . In both 7 of these alternative pathway activation assays CP appears to only partially block activation 8
suggesting that HAstV-1 CP suppresses hemolytic complement activity via the classical pathway 9 more than via the alternative pathway. 10
HAstV-1 CP inhibits iC3b, C5b-9 membrane attack complex and C4d formation. While 11 CP was found to suppress complement in hemolytic assays, it was unclear as to whether this 12 effect was due to activation and depletion of serum complement components, as occurs with 13 CVF, or as the result of inhibition of activation. To test these competing hypotheses, aliquots of 14 NHS alone, NHS + CP or NHS + CVF were incubated for 3 h at 37 o C and the amount of iC3b 15 produced was measured by immunoblot and an iC3b-specific ELISA. Upon activation of the 16 three pathways of the complement system, C3 is cleaved to C3a and C3b. Some C3b is further 17 cleaved to the 'inactive' form iC3b by soluble complement regulators in NHS (factor I plus 18 factor H). Utilizing an immunoblot with antibody specific for C3-fragments, two bands are 19 present for the uncleaved C3 control, C3-alpha (114 kDa) and C3-beta (75 kDa) (Fig. 7A, C3  20 lane). Cleavage of C3b to iC3b results in two cleavage products from the alpha chain of 68 kDa 21 (α' 1 ) and 42 kDa (α' 2 ) while the C3-beta chain remains invariant (Fig. 7A, iC3b with low-level, spontaneous activation of C3 (Fig. 7A, NHS lane) . In the CP containing sample, 1 very little of the 42 kDa iC3b product is observed (Fig. 7A , NHS + CP lane). In contrast, CVF 2 depletes the C3-alpha chain generating large amounts of the 42 kDa iC3b band (Fig. 7A, NHS +  3 CVF lane). To more precisely quantify the amount of iC3b generated, duplicate aliquots of these 4 samples were measured by iC3b-specific ELISA. Consistent with the immunoblot data, CP 5 suppressed iC3b formation to a greater extent than NHS alone (P = 0.0314) whereas NHS + CVF 6 generated significant amounts of iC3b consistent with the known actions of CVF to activate and 7 deplete the complement system (Fig. 7B) . Thus, even though HAstV-1 virions displayed similar 8 kinetics to CVF (see Fig. 2B ), these data show that the CP of this virus does not cause 9 complement activation resulting in cleavage of C3, suggesting that suppression of serum 10 complement activation occurs through an inhibitory mechanism. 11
To measure the effect of CP inhibition of serum complement on the terminal complement 12 cascade, aliquots of the samples used above were assayed for formation of the membrane attack 13 complex utilizing an ELISA specific for SC5b-9 complex formation. As shown in Figure 7C , for 14 NHS alone, a modest amount of SC5b-9 complex was detected whereas virtually no complex 15 was present in NHS treated with CP (P = 0.0286), suggesting no terminal complement cascade 16 activation. In CVF-treated serum, large amounts of SC5b-9 complex were generated as expected 17 for relentless activation and depletion. 18
The ability of CP to inhibit iC3b and SC5b-9 formation, coupled with its strong suppression 19 of the classical pathway (Fig. 5 ) led us to investigate if CP suppressed the complement system at 20 the level of C4, the second component of the classical pathway after C1. Upon activation of the 21 C1 complex, C4 is cleaved then C2 is cleaved to form the classical pathway C3-convertase (31). 22
An ELISA that detects a specific by-product of C4 activation (C4d) demonstrated that in the 23 presence of CP, serum generates very low levels of C4d in contrast to NHS alone (P = 0.0286) 1 (Fig. 7D) suggesting inhibition of spontaneous classical pathway activation. The classical 2 pathway activator heat-aggregated IgG greatly increased C4d generation, yet when CP was 3 added simultaneously with heat-aggregated IgG to NHS, C4d formation was greatly inhibited (P 4 = 0.0286) (Fig. 7D) . These results show that HAstV-1 CP can inhibit classical pathway 5 activation by a potent classical activator, heat-aggregated IgG, before C4 cleavage can occur, 6
suggesting that CP is a strong classical pathway inhibitor and that inhibition likely occurs at C1. 7
HAstV-1 CP binds to the A-chain of C1q. CP inhibition of the classical pathway led us to 8 speculate that CP interacts with one of the classical pathway factors (C1 complex, C4 or C2). To 9 ascertain whether CP binds to specific complement factors, we utilized a modified virus overlay 10 protein binding assay approach (3) . To this end, C1 complex and highly purified C2, C3 and C4 11
were mixed with SDS sample buffer lacking reducing agents, and loaded onto a 7.5% SDS-12 PAGE gel without boiling. Following electrophoresis, proteins were transferred to nitrocellulose, 13 blocked and then probed with or without purified CP in blocking solution for 1 h, after which the 14 blots were washed. CP binding was then detected with antisera to HAstV-1 (2) followed by 15 labeled secondary antibody. As shown in Figure 8A , a specific band of approximately 59 kDa, 16 consistent with a dimer of C1 chains, was present in the C1 lane while no binding was detected 17
for C2-C4. In the absence of the CP probe, no signal was detected for C1 (Fig. 8B) . The fact that 18 C1 is a multimolecular complex of C1q, C1r and C1s along with the fact that the gels were run 19 under non-reducing conditions without boiling the samples made it difficult to determine exactly 20 which component of C1 interacts with the viral CP. To address this, all 3 of the highly purified 21 constituents of the C1 complex (C1q, C1r, C1s) were boiled, reduced and loaded onto 12% SDS-22 PAGE gels, transferred to nitrocellulose and probed with or without CP as above. The blot 23 probed with CP detected a band of ~34 kDa in the C1 and C1q lanes whereas there was no signal 1 for BSA, C1r or C1s (Fig. 8C) . As expected, no signal was detected in the duplicate blot that did 2 not receive the CP probe (Fig. 8D) . The blots were stripped and reprobed with antisera to C1q, 3
C1r and C1s to reveal the individual protein constituents of C1 (Fig. 8E) . C1q is composed of six 4 subunits, each of which contains 3 polypeptide chains A, B, and C. As seen in the C1 and C1q 5 lanes, all 3 C1q chains react with C1q antisera and under reducing conditions chain C runs at 6 27.5 kDa, chain B runs at 31.6 kDa and chain A runs at 34.8 kDa (23). CP was found to overlay 7 precisely with the 34 kDa band corresponding to the A-chain of C1q in both the C1 and C1q 8 lanes. The band detected by CP at approximately 59 kDa seen in the non-reduced C1 lanes (Fig.  9 8A) we believe correspond to disulphide-bonded A-B C1q dimers. 10
Exogenous C1 can reconstitute hemolytic activity and C3 activation of CP-treated NHS. 11
Based on the overlay blot data, CP appears to interact with the A-chain of C1q. If C1 is 12 interacting with CP, then additional exogenous C1 should reconstitute hemolytic complement 13 activity. Thus, enough CP was added to NHS for 1 h inhibiting lysis approximately 50% (Fig.  14   9A ). Exogeneous C1 (10 µg) was then added to CP-treated NHS and hemolytic activity was fully 15 restored from 56% to 97% (P = 0.0286). Reconstitution of hemolytic activity did not occur when 16 BSA was substituted for C1, nor when additional C1 was added to CVF-treated NHS, suggesting 17 CP reversibly inhibits complement activation via C1. 18
To confirm the reversal of CP inhibition of complement activity by C1, the deposition of C3 19 on zymosan was measured (Fig. 9B) . Zymosan particles activate complement and serve as a 20 target for C3-fragment binding. Duplicate aliquots of NHS were incubated with CP or CVF for 1 21 h at 37 o C. After the incubation, C1 was added to the indicated samples followed by the addition 22 of zymosan to all samples. After 10 min at 37 o C, the samples were treated with methylamine to 23 cleave off bound C3-fragments that were measured in a C3-specific ELISA. NHS alone bound 1 substantial amounts of C3-fragments onto zymosan as expected, whereas CP-treated NHS bound 2 much lower levels of C3-fragments (Fig. 9B) . Addition of exogenous C1 to CP-treated NHS 3 increased C3-fragment binding again showing the ability of excess C1 to reconstitute 4 complement activity. As expected, addition of excess C1 to CVF-treated NHS did not 5 significantly increase C3 deposition. Taken together, these experiments suggest that CP inhibits 6 complement activation at C1 and the inhibition of the complement activation cascade is 7 reversible. experiments if the oligomerization state of the protein is critical for its observed activity on 13 complement, it is apparent that the coat protein retains complement activity regardless of its state 14 as soluble protein or in the context of an infectious, trypsin-cleaved virus particle. 15
CP interaction with C1, a novel method of complement inhibition by a virus. C1 initiates 16
activation of the classical pathway and links the adaptive and innate immune system by 17 recognizing antibody-bound pathogens (Fig 1) . It consists of a multimolecular complex formed 18 by the pattern recognition protein C1q that is associated with a calcium-dependent tetramer of 19 the serine proteases C1r and C1s (reviewed in 5). The 6 subunits of C1q each consist of the 3 20 protein chains A, B, and C which compose an N-terminal, triple-helical, collagen-like (stalk) 21 domain followed by a globular (head) domain. The head domain is the moiety responsible for 22 binding the conventional activating molecules, clustered IgG and IgM. However, other non-23 immunoglobulin molecules such as C-reactive protein, serum amyloid P, LPS and DNA may 1 also bind C1q (29). Binding of the globular head of C1q by the appropriate activating molecule 2 is thought to induce a conformational change in C1q that activates C1r, which in turn cleaves 3
C1s to initiate classical pathway activation (5). In serum, activation of C1 is tightly regulated by 4 C1-inhibitor, a protein of the serpin family which inactivates C1 by forming an extremely stable 5 complex to activated C1r and C1s (5). Our data suggest that CP inhibits complement activity at 6 C1 and directly binds the A chain of C1q, but the precise mechanism by which this inhibition 7 occurs is unknown. Unlike C1-inhibitor, CP does not have homology to serpin proteins and 8 appears to bind exclusively with C1q. Thus CP appears to inhibit C1 by a novel mechanism that 9 is under investigation. 10
Insights into astrovirus pathogenesis. Many enteric pathogens such as rotavirus (12) 11 initiate diarrhea by destroying enterocytes in the epithelium and inducing an increased 12 inflammatory response. However, astrovirus-induced diarrhea does not appear to result in 13 significant cell death or inflammation in humans or in an avian astrovirus animal model 14 (reviewed in 21). One of the important roles of complement is to trigger a robust inflammatory 15 (leukocyte) cell migration to infected tissues via the peptides mediators C3a/C5a which are 16 generated by cleavage of C3 and C5, respectively (8) . Inhibition of iC3b and SC5b-9 formation 17 by CP (Fig. 7) 
